Child With Inhibitors Against Alprolix Returns to Therapy After ITI

Child With Inhibitors Against Alprolix Returns to Therapy After ITI

309981

Child With Inhibitors Against Alprolix Returns to Therapy After ITI

The first documented case of a previously untreated hemophilia B patient developing inhibitors against the extended half-life therapy Alprolix was described in a report from Canada. The report also shows how combining routine administration of Alprolix with medications that suppress the immune system can be used to stop the production of inhibitors. “Immune tolerance induction using Fc-fusion-protein recombinant factor IX in severe haemophilia B” was published as a letter to the editor in the journal…

You must be logged in to read/download the full post.